Maas Group undergoes further strategic acquisition, expanding into the Melbourne market with the purchase of Dandy
Collins Foods has not surprised with its half year result, but updated guidance suggests anticipated second half margin recovery is no longer expected
Actinogen Medical is a biotech with a potentially “gazillion” dollar opportunity in its Alzheimer’s drug
A turn in sentiment has allowed Nanosonics shares to recover, with (some) broker views turning less negative
The headwinds that drove a soft FY22 for Select Harvests look to continue to challenge the company in the new fiscal year
United Malt’s FY22 was weak, as expected, but the company has guided to significant earnings growth ahead
Nufarm wraps up a strong year with guidance for modest growth ahead, surprising analysts who had largely predicted an earnings decline
Elders closes the year on a strong note, but heavy rainfall dampens the outlook for coming harvests
Medical imaging is back in demand in the post-covid world and Mach7 Technologies seems an undervalued player
Having brought a canine cancer treatment to market, Qbiotic’s focus has returned to treating two-legged cancers including melanoma and other difficult-to-treat cancers